Writing a new future for medicine
Tessera Therapeutics is a Flagship Pioneering biotechnology company pioneering Gene Writing, a novel genome engineering platform that uses mobile genetic elements to make permanent, programmable changes to the human genome. Unlike CRISPR-based editing, Gene Writing can make small and large alterations without double-strand DNA breaks. The company is advancing in vivo programs for rare diseases including alpha-1 antitrypsin deficiency and sickle cell disease, with Regeneron as a key development partner.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Dec 2024
Apr 2022
Jan 2021
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
